Maarten Altelaar, PhD

Maarten Altelaar obtained his PhD in 2007 from the Institute of Atomic and Molecular Physics in Amsterdam. During his scientific career he has focused on developing mass spectrometry (MS) based proteomics technologies and has applied these to address diverse biological questions. He received a VIDI grant in 2013 to study proteome-wide crosstalk mechanisms in cancer signaling and drug resistance. In 2019 he was appointed Professor of Pharmaceutical Proteomics at Utrecht University, where his group specialized in quantitative (phospho)proteomics to study cellular signaling dynamics and protein-protein interactions in health and disease. Maarten has contributed to over 175 peer-reviewed publications, is treasurer and board member of the International Mass Spectrometry Foundation (IMSF) and headed the proteomics facility at the Netherlands Cancer Institute between 2013 and 2022. In 2022 he took on the position of Executive Director at Ambagon Therapeutics, heading the proteomics and biochemistry efforts.